Video

Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events (AEs) with bevacizumab (Avastin) in ovarian cancer.

In a study on the long-term use of bevacizumab in patients with ovarian cancer, investigators aimed to characterize the AEs. Essel says that the AEs investigators were the most concerned about prior to the study were cardiovascular events and hypertension. However, Essel says that patients who did not experience an increase in blood pressure initially did not experience it subsequently.

The data provides comfort in the decision to put a patient on long-term bevacizumab, Essel says. If a patient with platinum-sensitive recurrent ovarian cancer is given chemotherapy based off data from the GOG213 or OCEANS trials and does well, then physicians can feel confident that additional AEs will not come up with continued use of bevacizumab.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD